Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...
Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.19 which represents a slight increase of $0.43 or 0.48% from the prior close of $89.76. The stock opened at $89 ...
DelveInsight's "Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth ...
Women - especially teen girls and young women living in sub-Saharan Africa - are disproportionately impacted by HIV globally, with about 3,100 acquiring HIV each week. They've also historically been ...
In Uganda, women and girls are more affected by HIV. Out of 1.4 million people living with the disease, 860 000 are women and ...
44m
As the U.S. prepares to welcome a new presidential administration, leaders from business, public health, and community ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares closed last ...
Remdesivir plus dexamethasone vs dexamethasone alone reduces the risk of mortality among patients hospitalized with COVID-19.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback